The Swiss group shells out $2bn for Synnovation’s mutation-selective PI3Kα inhibitor.
ApexOnco Front Page
Recent articles
A unique VEGF trispecific and mRNA-based T-cell engager will also be featured at the congress.
The group’s first pivotal readout, in second-line pancreatic cancer, is coming.
A trial of one KRAS G12D inhibitor is halted early, while that of another sees tox troubles.
The Kandlelit-013 trial of calderasib plus Keytruda in adjuvant NSCLC will start in April.
Cullgen’s oncology portfolio features TRK, GSPT1 and CDK2 degraders.
The Japanese group will soon start a trial of its Reblozyl rival in first-line MDS.
But now it must show that varseta-M can move into a registrational trial.
